IVF Hartmann Holding AG (LON:0QQM)
London
· Delayed Price · Currency is GBP · Price in CHF 158.50
+7.70 (5.11%)
At close: Apr 17, 2025
IVF Hartmann Holding AG Revenue
In the year 2024, IVF Hartmann Holding AG had annual revenue of 159.03M CHF with 7.23% growth. IVF Hartmann Holding AG had revenue of 82.52M in the half year ending December 31, 2024, with 5.47% growth.
Revenue
159.03M CHF
Revenue Growth
+7.23%
P/S Ratio
2.39
Revenue / Employee
588.80K CHF
Employees
270
Market Cap
335.21M GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 159.03M | 10.72M | 7.23% |
| Dec 31, 2023 | 148.31M | -2.84M | -1.88% |
| Dec 31, 2022 | 151.15M | 6.35M | 4.38% |
| Dec 31, 2021 | 144.80M | -29.16M | -16.76% |
| Dec 31, 2020 | 173.96M | 34.94M | 25.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Oxford Nanopore Technologies | 183.19M |